|
PCYOX1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.28230000000051E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.789100E-04 |
| Normal-vs-Stage2 |
7.119300E-03 |
| Normal-vs-Stage3 |
2.48800000000049E-05 |
| Normal-vs-Stage4 |
1.61296999999783E-05 |
| Stage1-vs-Stage2 |
9.872200E-01 |
| Stage1-vs-Stage3 |
2.862400E-01 |
| Stage1-vs-Stage4 |
8.258500E-02 |
| Stage2-vs-Stage3 |
4.547200E-01 |
| Stage2-vs-Stage4 |
1.611240E-01 |
| Stage3-vs-Stage4 |
3.530800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.95830000002417E-06 |
| Normal-vs-AfricanAmerican |
1.087560E-01 |
| Normal-vs-Asian |
3.942300E-03 |
| Caucasian-vs-AfricanAmerican |
2.253000E-01 |
| Caucasian-vs-Asian |
7.719600E-01 |
| AfricanAmerican-vs-Asian |
4.298200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.404920E-03 |
| Normal-vs-Female |
1.69633000000058E-05 |
| Male-vs-Female |
3.993400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.821800E-04 |
| Normal-vs-Age(41-60Yrs) |
9.87540000000342E-05 |
| Normal-vs-Age(61-80Yrs) |
6.16999999999424E-05 |
| Normal-vs-Age(81-100Yrs) |
2.606400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.097800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.444000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.548800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.903400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.777200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.626400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.372140E-04 |
| Classical-VS-Follicular |
1.827020E-01 |
| Classical-VS-Other |
2.725400E-01 |
| Classical-VS-Normal |
8.427100E-04 |
| Tall-VS-Follicular |
3.770300E-02 |
| Tall-VS-Other |
7.319400E-01 |
| Tall-VS-Normal |
1.13190000039509E-07 |
| Follicular-VS-Other |
5.436000E-01 |
| Follicular-VS-Normal |
3.210300E-04 |
| Other-VS-Normal |
2.164500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.567790E-04 |
| Normal-vs-N1 |
1.89910000003568E-06 |
| N0-vs-N1 |
5.144100E-02 |
|
|
